Effect of Feeding Jejunostomy on Sarcopenia in Patients With Esophageal Cancer

NCT06712706 | Active Not Recruiting

• 1 other identifier: BASEC 2024-01793
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Participants were diagnosed with esophageal cancer needing chemo- or radiochemotherapy before the potentially curing surgery consisting of esophagectomy. At the time of diagnosis, in all participants, a laparoscopy to complete staging was performed. In some patients, a feeding jejunostomy tube (FJT) was placed at the time of staging laparoscopy; in others, the FJT was placed at the time of esophagectomy. A common risk factor for higher morbidity and mortality is sarcopenia, a condition associated with low skeletal muscle. This study aims to determine whether the timing of the FJT placement affects the progress of sarcopenia.

Conditions

Esophageal Cancer; Esophageal Carcinoma; Sarcopenia; Feeding Tube

Keywords

feeding jejunostomy tube; enteral feeding route before or after neoadjuvant therapy; feeding jejunostomy tube at staging laparoscopy; feeding jejunostomy in esophagel cancer; sarcopenia in esophageal cancer; effect of enteral feeding on sarcopenia; sarcopenia in esophageal cancer patients

Outcome Measures

Primary Outcomes (1)

• Quantification of the effect of timing of FJT placement on sarcopenia in patients with advanced stages of esophageal cancer in curative cancer treatment.

  This will be measured by the skeletal muscle index (SMI) at three points: the first SMI is measured at the time of diagnosis, the second preoperatively at re-staging after completion of neoadjuvant therapy, and the third measurement is six months postoperatively. We expect that regular enteral feed through FJT during neoadjuvant therapy leads to higher SMI or less progress of sarcopenia compared to FJT placement at esophagectomy.

  For each patient the investigated period is under one year. It starts with the time of diagnosis until approximately 6 months after esophagectomy.

Secondary Outcomes (2)

• Major complications

  For each patient the investigated period is under one year. It starts with the time of diagnosis until approximately 6 months after esophagectomy.

• Overall length of stay

  For each patient the investigated period is under one year. It starts with the time of diagnosis until approximately 6 months after esophagectomy.

Study Arms (1)

Patients with esophageal cancer receiving neoadjuvant therapy and an jejunal feeding tube

Included are: * Adult patients aged 18 years and above at the time of diagnosis. * Advanced-stage esophageal cancer or cancer of the esophageal junction and treated with curative intent, including neoadjuvant treatment. * Patients who received an FJT before neoadjuvant treatment or during definitive surgery. * Patients treated between 2017 and 2024 in the single institution of the City Hospital Zürich Triemli and completed 6 months of follow-up or died by 31.12.2024. Patients receiving the FJT at staging laparoscopy will be compared to patients receiving FJT at the time of esophagectomy.

Procedure: Feeding jejunostomy placement; Procedure: Feeding jejunostomy placement at esophagectomy

Interventions

Feeding jejunostomy placement PROCEDURE

Placement of feeding jejunostomy at staging laparoscopy

Also known as: Early placement of FJT

Patients with esophageal cancer receiving neoadjuvant therapy and an jejunal feeding tube

Feeding jejunostomy placement at esophagectomy PROCEDURE

Placement of feeding jejunostomy at esophagectomy

Also known as: Late placement of FJT

Patients with esophageal cancer receiving neoadjuvant therapy and an jejunal feeding tube

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated between 2017 and 2024 in the single institution of the City Hospital Zürich Triemli and completed a 6-month follow-up or died by 31.12.2024.

You may qualify if:

• Adult patients aged 18 years and above at the time of diagnosis.
• Advanced-stage esophageal cancer or cancer of the esophageal junction and treated with curative intent, including neoadjuvant treatment.
• Patients who received an FJT either before neoadjuvant treatment or during definitive surgery.

You may not qualify if:

• Insufficient data for analysis
• Written rejection of general consent

Sponsors & Collaborators

• Stefan Gutknecht: lead

Study Sites (1)

Stadtspital Zürich

Zurich, 8063, Switzerland

Location

MeSH Terms

Conditions

Esophageal Neoplasms; Sarcopenia

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Stefan Gutknecht, Dr. med.

  Stadtspital Zürich

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 26, 2024
• First Posted: December 2, 2024
• Study Start: November 30, 2024
• Primary Completion: January 31, 2025
• Study Completion (Estimated): June 30, 2026
• Last Updated: April 23, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)